SUNZEN BIOTECH BHD
KLSE (MYR): SUNZEN (0148)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.315
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Financial
T4Q
31-Mar-2021
2020
31-Mar-2021
2019
31-Mar-2021
2018
31-Mar-2021
2017
31-Mar-2021
Total assets
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
Total current assets
238
1000
110
900
600
Cash & equivalents
238
1000
110
900
600
Short term investments
238
1000
110
900
600
Total receivables, net
238
1000
110
900
600
Accounts receivable - trade, net
238
1000
110
900
600
Other receivables
238
1000
110
900
600
Total inventory
238
1000
110
900
600
Inventories - work in progress
238
1000
110
900
600
Inventories - progress payments & other
238
1000
110
900
600
Inventories - finished goods
238
1000
110
900
600
Inventories - raw materials
238
1000
110
900
600
Total non-current assets
238
1000
110
900
600
Long term investments
238
1000
110
900
600
Note receivable - long term
238
1000
110
900
600
Investments in unconsolidated subsidiaries
238
1000
110
900
600
Other investments
238
1000
110
900
600
Net property/plant/equipment
238
1000
110
900
600
Gross property/plant/equipment
238
1000
110
900
600
Accumulated depreciation, total
238
1000
110
900
600
Deferred tax assets
238
1000
110
900
600
Net intangible assets
238
1000
110
900
600
Other current assets, total
238
1000
110
900
600
Total liabilities
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
Total current liabilities
-238
-1000
-110
-900
-600
Total non-current liabilities
-238
-1000
-110
-900
-600
Long term debt
238
1000
110
900
600
Long term debt excl. lease liabilities
238
1000
110
900
600
Capital and operating lease obligations
238
1000
110
900
600
Provision for risks & charge
-238
-1000
-110
-900
-600
Deferred tax liabilities
-238
-1000
-110
-900
-600
Other liabilities, total
-238
-1000
-110
-900
-600
Total equity
-238
-1.64%
-1000
+11.55%
-110
+81.66%
-900
-13.16%
-600
+235.36%
Total liabilities & shareholders' equities
238B
1000B
110B
900B
600B
Total debt
238
1000
110
900
600
Book value per share
-238
-1000
-110
-900
-600
Discussions
5 people like this. Showing 50 of 2,218 comments
caught some at 0.31... cheap & nice to hold... if this week can climb back like you say then nice lor..
2024-08-06 16:01
next qr should see some improvement with the positive growth of biotech industry
2024-08-07 16:20
0.31-0.32 is a steady & cheap entry price now, Sunzen entering the healthcare sector will push the price further up
2024-08-08 15:07
Strong growth every quarter, Sunzen future prospect is really bright with new acquisition
2024-08-09 16:10
Next quarter's revenue and net profit will both increase quarter-on-quarter and year-on-year, I believe
2024-08-12 20:08
Sunzen has decreased current liabilities to 6.3% of total assets over this period. Good sign
2024-08-13 16:15
I just watched it. Must say the new management seems to be doing the right thing compare to the previous one. At least now SUNZEN is no longer losing money but making profit
1 month ago
Hopes the Xmegami lenglui will buy in sunzen also since their earning so high every month
1 month ago
Watched the technical analysis here https://youtu.be/9V0_mkxG1sw?si=M-l0iuIJeU4w9q5Q
1 month ago
Dow Jones
Dow Jones Industrial Average
42,011.59
-184.93
0.43%
Nasdaq
NASDAQ Composite
17,918.47
-6.64
0.03%
1 month ago
Share price still steady after that, biggie0000. We wait for the next rally to come
2 weeks ago
As consumers pay more and more attention to preventive health care and natural remedies, Sunzen's traditional Chinese medicine and human health supplement products have huge growth potential
2 weeks ago
Nice grab, gloveshapiro. If the QR is good as expected, it probably will break 35 cents
2 weeks ago
Sunzen Biotech eyes bigger share of China bird’s nest market. Sunzen subsidiary Ecolite Biotech Manufacturing Sdn Bhd has received approval from China’s customs authority in October last year to export its bottled bird’s nest to the country up to 2028.
1 week ago
The demand for edible bird’s nest products is indeed strong in China, Hong Kong, and other parts of Southeast Asia. The Chinese market, in particular, is one of the largest consumers of bird’s nests, driven by a cultural preference for traditional health products and rising disposable incomes
1 week ago
Sunzen's loan financing business is expected to continue to grow given the increasing trend in the number of applications and approvals, mainly due to our ability to provide fast and efficient services and structure more flexible loan packages to meet the needs of the SME market.
3 days ago
Acquisition of Eye Nation Medical is expected to contribute positively to the future financial performance of the Sunzen group, enhancing the group’s revenue and profitability, as it is secured by a profit guarantee of an audited profit after tax of RM2.60 million over the next two financial years
1 day ago
Then SUNZEN will be able to achieve over RM1 million of net profit in the next quarter 😀
13 hours ago
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
1
2
Good Articles to Share
3
4
Koon Yew Yin's Blog
Why all plantation companies will continue to report more profit - Koon Yew Yin
5
AmInvest Research Reports
6
7
save malaysia!
8
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Wixson
Great, SUNZEN still managed to stay above 30 cents today 👏
2024-08-05 19:43